Effect of isoprinosine on HIV antigenaemia.

Abstract

OBJECTIVE:

The objective of this study was to evaluate the effect of isoprinosine on HIV-antigen expression in HIV-positive patients without AIDS.

DESIGN:

Serum samples from anti-HIV-positive patients without AIDS participating in a double-blind, placebo-controlled trial of isoprinosine in the treatment of HIV infection were analysed for the presence of HIV antigen.

SETTING:

Data and samples were collected from the 21 medical centres who participated in the Scandinavian multicentre placebo-controlled isoprinosine study.

PATIENTS, PARTICIPANTS:

Samples were available from 19 of 21 participating centres. Of 866 patients who enrolled, baseline serum samples were available for 642 (74%; 308 isoprinosine- and 334 placebo-treated patients).

INTERVENTIONS:

Treatment was 1 g isoprinosine administered orally three times a day or matching placebo for 24 weeks.

MAIN OUTCOME MEASURES:

Comparison of HIV-antigen levels before and during treatment in both the isoprinosine-treated group and the placebo-treated group of patients.

RESULTS:

During the study, AIDS developed in 19 patients; 17 of whom were receiving placebo treatment and two isoprinosine. The proportion of HIV-antigen-positive patients developing AIDS during treatment was significantly different from the proportion of HIV-antigen-negative patients in whom AIDS developed (6 versus 2%; P = 0.02). No significant changes in HIV-antigen levels were observed between the isoprinosine- and the placebo-treated group of HIV-antigen-positive patients. Median HIV-antigen levels did not change significantly in either the isoprinosine- or the placebo-treated group.

CONCLUSION:

Our results suggest that isoprinosine does not have antiviral activity against HIV in vivo.

• Authors: L L Teglbjaerg, S Kroon, E Sandström, T Moestrup, B G Hansson, B F Vestergaard
• Journal: AIDS (London, England) (AIDS) Vol. 6 Issue 2 Pg. 199-201 (Feb 1992) ISSN: 0269-9370 [Print] England
• PMID: 1373064 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• HIV Antigens
• Inosine Pranobex

Topics

• Acquired Immunodeficiency Syndrome (immunology)
• CD4-Positive T-Lymphocytes
• Double-Blind Method
• HIV Antigens (blood, drug effects)
• HIV Seropositivity (drug therapy, immunology)
• Humans
• Inosine Pranobex (therapeutic use)
• Leukocyte Count